Impact of a pharmacist-delivered discharge and follow-up intervention for patients with acute coronary syndromes in Qatar: a study protocol for a randomised controlled trial.

ABSTRACT:

Introduction

Acute coronary syndrome (ACS) is one of the leading causes of morbidity and mortality worldwide. Secondary cardiovascular risk reduction therapy (consisting of an aspirin, a β-blocker, an ACE inhibitor or an angiotensin II receptor blocker and a statin) is needed for all patients with ACS. Less than 80% of patients with ACS in Qatar use this combination after discharge. This study is aimed to evaluate the effectiveness of clinical pharmacist-delivered intervention at discharge and tailored follow-up postdischarge on decreasing hospital readmissions, emergency department (ED) visits and mortality among patients with ACS.

Methods and analysis

A prospective, randomised controlled trial will be conducted at the Heart Hospital in Qatar. Patients are eligible for enro

SUBMITTER: Zidan A 

PROVIDER: S-EPMC5129077 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature